Skip to content
-
Subscribe to our newsletter & never miss our best posts. Subscribe Now!
Itfy.in

At Itfy, we are dedicated to revolutionizing the way you receive news. Our mission is to provide timely, accurate, and personalized news updates using cutting-edge AI technology. Stay informed, stay ahead with us.

Itfy.in

At Itfy, we are dedicated to revolutionizing the way you receive news. Our mission is to provide timely, accurate, and personalized news updates using cutting-edge AI technology. Stay informed, stay ahead with us.

  • Home
  • News Updates
    • Latest News
    • Entertainment News
    • Northeast News
  • Technology
    • Digital Transformation
    • Artificial Intelligence
    • Machine Learning
    • Generative AI
    • Cybersecurity
  • Education & Growth
    • Education
    • Lifelong Learning
    • Parenting
    • Career Growth
  • Startup & Entrepreneurship
    • Remote Work
    • Startups
    • Digital Marketing
    • Social Media
    • Entrepreneurship
    • Lean Thinking
    • Personal Finance
  • Climate Justice
    • Climate Tech
  • Health & Wellness
    • Mental Health
  • Tourism
  • Home
  • News Updates
    • Latest News
    • Entertainment News
    • Northeast News
  • Technology
    • Digital Transformation
    • Artificial Intelligence
    • Machine Learning
    • Generative AI
    • Cybersecurity
  • Education & Growth
    • Education
    • Lifelong Learning
    • Parenting
    • Career Growth
  • Startup & Entrepreneurship
    • Remote Work
    • Startups
    • Digital Marketing
    • Social Media
    • Entrepreneurship
    • Lean Thinking
    • Personal Finance
  • Climate Justice
    • Climate Tech
  • Health & Wellness
    • Mental Health
  • Tourism
Close

Search

  • https://www.facebook.com/
  • https://twitter.com/
  • https://t.me/
  • https://www.instagram.com/
  • https://youtube.com/
Subscribe
Home/News/Stunning Growth: Moderna (MRNA) Q2 2024 Earnings Crush Expectations
News

Stunning Growth: Moderna (MRNA) Q2 2024 Earnings Crush Expectations

By adminitfy
August 1, 2024 2 Min Read

Moderna reported better-than-expected second-quarter revenue but lowered its full-year sales forecast due to anticipated lower sales in Europe and increased competition for respiratory vaccines in the U.S. The biotech firm now expects 2024 product revenue between $3 billion and $3.5 billion, down from a prior estimate of $4 billion. Contributing factors include lower projected sales and potential deferred international revenue into 2025.

Moderna has commenced shipping its newly approved respiratory syncytial virus (RSV) vaccine, mRESVIA, in the U.S., targeting older adults. This follows its successful Covid vaccine launch, although demand for the latter has sharply declined as the pandemic wanes. CEO Stephane Bancel highlighted heightened competition for both RSV and Covid vaccines, noting that mRESVIA entered a market already served by Pfizer and GSK.

Despite near-term challenges, Bancel indicated ongoing negotiations with European governments to secure Covid vaccine supply contracts. However, fiscal constraints and competing agreements, particularly the EU’s pact with Pfizer and BioNTech, complicate these efforts. Economic pressures, including the war in Ukraine, are also affecting government budgets.

Financially, Moderna posted a second-quarter revenue of $241 million, surpassing the expected $132 million but marking a 37% drop from the previous year due to an anticipated move to a seasonal Covid vaccine model. The company reported a net loss of $1.28 billion, or $3.33 per share, which was slightly better than the expected $3.39 per share loss. Cost-cutting measures contributed to the narrower-than-expected loss, with sales costs plummeting 84% year-over-year.

Research and development expenses rose 6% to $1.2 billion, driven by increased personnel costs, while selling, general, and administrative expenses fell 19% to $268 million.

Despite the financial challenges, Moderna’s stock has risen nearly 20% this year, buoyed by confidence in its extensive pipeline and mRNA technology. The company has 45 products in development, including a combination Covid and flu shot and a personalized cancer vaccine with Merck, with some products potentially launching by 2025.

Original Story https://www.cnbc.com/2024/08/01/moderna-mrna-earnings-q2-2024.html
Category :
Tags:

Author

adminitfy

Follow Me
Other Articles
Previous

Heroic Road-Cum-Embankment in Dhubri Saves Assam’s Precious Cropland and Habitats from Devastating Floods

Next

Breaking: Life-Saving Cashless Treatment Scheme Unveiled for Road Accident Victims in Assam and Chandigarh – Northeast News

Search...

Recent Posts

  • Assam Congress to Hold ‘Save Constitution’ March in Guwahati Nov 26
    Assam Congress to Hold ‘Save Constitution’ March in Guwahati Nov 26
    by adminitfy
    November 22, 2026
  • Empowering Northeast India: CII’s CSR Connect Event Ignites Social Development
    by adminitfy
    July 3, 2024
  • Urgent Crisis: Northeast on High Alert as Death Toll Tragically Rises in Assam
    by adminitfy
    July 3, 2024
  • Triumphant Breakthrough: Security Forces Successfully Capture 4 Insurgents in Manipur Operation
    by adminitfy
    July 3, 2024

Welcome to the ultimate source for fresh perspectives! Explore curated content to enlighten, entertain and engage global readers.

  • Facebook
  • X
  • Instagram
  • LinkedIn

Latest Posts

  • Assam Congress to Hold ‘Save Constitution’ March in Guwahati Nov 26
  • Nepal PM Balen Shah Seeks $2B India Package Before Modi Meeting
  • Gunotsav 2027: Assam Govt Revises Schedule, Assessment Begins Jan 6
  • Pawan Kalyan Orders Probe Into Jana Sena Activist’s Death
  • Architecting Resilience: Trust and Critical Infrastructure in the Age of Outages
  • November 2026 (696)
  • October 2026 (646)
  • September 2026 (524)
  • August 2026 (1001)
  • July 2026 (986)
  • June 2026 (963)
  • May 2026 (922)
  • April 2026 (1525)
  • March 2026 (1522)
  • February 2026 (1252)
  • January 2026 (968)
  • December 2025 (942)
  • November 2025 (853)
  • October 2025 (869)
  • September 2025 (733)
  • August 2025 (810)
  • July 2025 (720)
  • June 2025 (1244)
  • May 2025 (2201)
  • April 2025 (1481)
  • March 2025 (2020)
  • February 2025 (1159)
  • January 2025 (1440)
  • December 2024 (1499)
  • November 2024 (1771)
  • October 2024 (1815)
  • September 2024 (1750)
  • August 2024 (1458)
  • July 2024 (1268)

Contact

Email

info@itfy.in

Location

INDIA

Copyright 2026 — Itfy.in. All rights reserved.